ASHM's Beyond the C- Hepatitis C Elimination in your practice aims to increase the number of patients screened, tes… https://t.co/YcAqoehanN
ASHM Report Back
Clinical posts from members and guests of the Australasian Society for HIV, Viral Hepatitis and Sexual Health Medicine (ASHM) from various international medical and scientific conferences on HIV, AIDS, viral hepatitis, and sexual health.
Targeted implementation of PrEP in NSW
PrEP has been used in NSW by high risk individuals since 2011, with a significant increase in 2016.
It has been limited by cost and availability.
Who should have access to PrEP, given limited resources? - The high risk patient approach.
Demonstration study - PRELUDE 2014-2016 government purchased generics
Estimated 4% (12 of 300) of PRELUDE study patients would have seroconverted, but none did.
Individuals are usually highly motivated.
Blood tests in these studies suggest very high levels of adherence.
The implementation trial EPIC-NSW.
Estimated that there must be 3700 high-risk individuals in NSW
It was estimated that the highest risk 11% of the gay community would comprise 3700 people, but so far we have recruited 4000.
EPIC aimed to target this group and enroll them on a PrEP study.
EPIC-NSW estimates 150 participants should have seroconverted by the end of the study, it is early yet, but so far none have.